Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Investor Presentation (March 2022)

13 slides from Neuroscientific Biopharmaceuticals's investor presentation, Mar 24, 2022

  1. Slide 1: Novel Drug Therapies for Neurodegenerative Conditions

    NOVEL DRUG THERAPIES FOR For personal use only NEURODEGENERATIVE CONDITIONS COMPANY PRESENTATION March 2022 ASX:NSB

  2. Slide 2: Disclaimer

    DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  3. Slide 3: Company Highlights

    For personal use only COMPANY HIGHLIGHTS DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTIC DRUGS Developing peptide-based drugs with disease modifying potential for neurodegenerative conditions EMTINB™: LEAD DRUG CANDIDATE WITH DISEASE MODIFYING POTENTIAL A first-in-class treatment for Alzheimer’s disease,

  4. Slide 4: Company Overview

    COMPANY OVERVIEW CAPITAL STRUCTURE SHARE PRICE CHART For personal use only ASX CODE NSB SHARE PRICE (23/04/22) $0.29 SHARES ON ISSUE 143.5M UNLISTED OPTIONS 16.8M MARKET CAPITALISATION $42M NET CASH POSITION $9.5M TOP 20 SHAREHOLDERS 48% BOARD & MANAGEMENT PAUL RENNIE MATT LIDDELOW DR ANTON UVAROV S

  5. Slide 5: Addressing Global Unmet Medical Need in Neurodegenerative Conditions

    ADDRESSING GLOBAL UNMET MEDICAL NEED IN NEURODEGENERATIVE CONDITIONS For personal use only The underlying cause of most neurodegenerative conditions is not known ALZHEIMER’S DISEASE MULTIPLE SCLEROSIS OPTIC NEUROPATHIES 40M PATIENTS WORLDWIDE $27B MARKET VALUE 70M INCIDENCE GLAUCOMA OF MOST SEVERE T

  6. Slide 6: EmtinB: Lead Drug Candidate with Disease Modifying Potential

    EMTINB™: LEAD DRUG CANDIDATE WITH DISEASE MODIFYING POTENTIAL EmtinB™ promotes cell survival and regeneration, and reduces inflammation in For personal use only neurodegenerative conditions MODELLED ON HUMAN PROTECTIVE PROTEIN MT-II EMTINB™ OH K K K  Large body of published data demonstrating prote

  7. Slide 7: EmtinB Disease Modifying Effect in Alzheimer's Disease

    For personal use only EMTINB™ DISEASE MODIFYING EFFECT IN ALZHEIMER’S DISEASE ALZHEIMER’S DISEASE – PREVENTING COGNITIVE DECLINE AD MOUSE MODEL  Validated in the gold-standard animal model  Protected tissue of the brain and improved memory  Reduced inflammation 7

  8. Slide 8: EmtinB Disease Modifying Effect in Multiple Sclerosis

    For personal use only EMTINB™ DISEASE MODIFYING EFFECT IN MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS – POTENTIAL TO TREAT ALL STAGES  Increased the number of myelin-forming cells (oligodendrocytes)  Increased myelin production  Increased survival and regeneration of neurons Recently announced data dem

  9. Slide 9: EmtinB Disease Modifying Effect in Glaucoma

    For personal use only EMTINB™ DISEASE MODIFYING EFFECT IN GLAUCOMA GLAUCOMA – PROTECTING THE OPTIC NERVE AND PREVENTING VISION LOSS NOT TREATED EMTINB TREATED  Performed in pig model; structure of the eye very similar to humans  Prevented damage to retinal cells  Prevented damage to the optic ner

  10. Slide 10: EmtinB Development Pipeline

    For personal use only EMTINB™ – DEVELOPMENT PIPELINE INDICATION RESEARCH SAFETY & TOX PHASE I ALZHEIMER’S DISEASE 1H CY2022 MULTIPLE SCLEROSIS The same safety & toxicology data from the NEUROLOGY indication above will be used to support MS GLAUCOMA 2H CY2022 ISCHEMIC NEUROPATHY OPHTHALMOLOGY PULMONA

  11. Slide 11: Partnering with Leading Research Organisations

    PARTNERING WITH LEADING RESEARCH ORGANISATIONS For personal use only NON-CLINICAL RESEARCH CLINICAL RESEARCH 11

  12. Slide 12: Transitioning to Clinical Development

    TRANSITIONING TO CLINICAL DEVELOPMENT NSB is progressing EmtinB™ to Phase I clinical trials in 1H CY2022 For personal use only FIRST-IN-HUMAN EmtinB™ PHASE I STUDY REGULATORY DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III REVIEW & RESEARCH TOXICOLOGY CLINICAL TRIAL CLINICAL TRIAL CLINICAL TRIAL AP

  13. Slide 13: Contact Information

    For personal use only CONTACT INFORMATION For more information: Matt Liddelow CEO & Managing Director E: ml@neuroscientific.com www.neuroscientific.com

NeuroScientific Biopharmaceuticals — Investor Presentation (March 2022) on 6ix